Navigation Links
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Date:2/14/2008

PRINCETON, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the first fiscal quarter of 2008 ended December 31, 2007. Pharmasset reported a net loss attributable to common stockholders of $12.2 million, or ($0.57) per share for the first fiscal quarter of 2008, as compared to net income attributable to common stockholders of $3.6 million, or $0.33 per diluted share for the same period in fiscal 2007.

Revenues were $0.5 million during the first fiscal quarter of 2008, which consisted of the amortization of payments received from Roche from the hepatitis C virus (HCV) collaboration agreement that were previously recorded as deferred revenue. Revenues for the same period in fiscal 2007 were $8.1 million, which included a $7.5 million milestone payment received from Roche. Investment income was $0.9 million during the first fiscal quarter of 2008 compared to $0.4 million during the same period in 2007. The $0.5 million increase in the first fiscal quarter of 2008 was due to higher average invested cash balances.

Total costs and expenses for the first fiscal quarter of 2008 were $13.2 million as compared to $4.6 million for the same period in fiscal 2007. The $8.6 million increase in operating expenses for the first fiscal quarter of 2008 was primarily due to a $7.0 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, as well as approximately $1.6 million in drug discovery, compensation, insurance, audit and non-cash stock compensation expenses
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. CEL-SCI Corporation Reports First Quarter Financial Results
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)...   LabStyle Innovations Corp . (OTCQB: DRIO), ... announced that it has closed a $4.2 million ... stock and warrants.  No placement agent was used ... expects to secure net proceeds of approximately $4.1 ... intends to use the net proceeds from the ...
(Date:9/23/2014)... --  MedNet Solutions , a global life sciences technology company ... that it will once again be a Silver Sponsor of ... be held this year from September 28 to October 1 ... in conjunction with representatives from many of its ... attendance, will be providing demonstrations of iMedNet EDC ...
(Date:9/23/2014)... and DUBLIN , Sept. 23, ... or the "Company"), a biotechnology company pioneering the ... diseases in emerging nations, today announced that the ... stock for DTC,s Deposit and Withdrawal at Custodian ... Service ("FAST") transfer agent as the distribution point. ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5MedNet Solutions - Proud To Sponsor The SCDM 2014 Annual Conference 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... (Nasdaq: ONXX ) today announced that it will ... Conference on Wednesday, March 9, 2011 at 11:00 a.m. Eastern ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... WASHINGTON, March 2, 2011 A new ad ... S.B. 2445 would raise taxes on prescription drug benefits ... to reduce health care costs for Mississippi families and ... S.B. 2445 would also put the State ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. ... low birth weights, breast milk is more likely than a ... as cytomegalovirus (CMV), a new study finds. The researchers ... all of whom weighed 3.3 pounds or less and many ... infection, to see whether breast milk or transfusions carried the ...
(Date:9/23/2014)... -- Both drinking and getting drunk at an early ... high school students, a new study suggests. The ... who drink, could help expand alcohol-prevention efforts aimed at ... them from becoming binge drinkers, the researchers suggested. , ... use and progression to first heavy use as risk ...
(Date:9/23/2014)... What information do patients need to ... (NQF) released a report ( http://bit.ly/1DwekE9 ), consumer ... ( http://bit.ly/1tX3lzA ) resulting from an in-depth look ... define affordability, and what information and changes are ... healthcare at the lowest possible cost. ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2
... genome of a novel strain of Clostridium botulinum , ... strain produces an unusual botulinum neurotoxin, known as type A5 ... following a case of wound botulism. Professor Mike ... Research (IFR) study Clostridium botulinum . Their expertise ...
... who comes to a health care centre does increase the ... a new study confirms. The study, led by Patricia ... St. Michael,s Hospital, represents a major reversal of thinking about ... intimate partner violence. Until now, the research and health ...
... ISRAEL, March 7, 2011 Elderly drivers are half as ... limited field of view, and compensate in part by driving ... the Negev (BGU) researchers. In the online edition ... reaction times and perception of pedestrians as hazards between experienced ...
... a year on remediation at hazardous waste sites, with ... Yet according to Rolf Halden, a researcher at Arizona ... of limited value. Under a new three-year, $1.15 ... assistant director at the Institute,s Swette Center for Environmental ...
... AstraZeneca HealthCare Foundation program, Connections for Cardiovascular HealthSM, today ... University of Michigan Health System to expand Project Healthy ... and is designed to reduce childhood obesity and its ... that it lowers total cholesterol and blood pressure in ...
... (HealthDay News) -- The sooner rehabilitation begins after knee ... research suggests. In the study, published March 7 ... compared more than 150 patients who began rehabilitation within ... control group of patients who began rehabilitation 48 to ...
Cached Medicine News:Health News:Genome sequencing used to assess a novel form of Clostridium botulinum 2Health News:Universal screening programs can uncover abuse, study finds 2Health News:Elderly see pedestrians half as often as younger drivers, according to Ben-Gurion U. researchers 2Health News:Monitoring waste in groundwater (without all the waste) 2
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Therapeutic Drug Calibrator Series...
Medicine Products: